| Zhang |
NCT06683651: A Study in Chinese Patients With Acquired Blepharoptosis |
|
|
| Recruiting | 3 | 180 | RoW | STN1013800 ophthalmic solution, STN1013800 ophthalmic solution Liquid Base, without STN1013800 | Santen Pharmaceutical Co., Ltd. | Blepharoptosis | 06/26 | 06/26 | | |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
NCT05751967: Fenofibrate Combined with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis |
|
|
| Recruiting | 3 | 150 | RoW | Placebo Combined With Ursodeoxycholic Acid, UDCA 13-15mg/kg/d, Fenofibrate Combined With Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
NCT06174402: Fenofibrate in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis |
|
|
| Recruiting | 2/3 | 184 | RoW | Fenofibrate, Placebo, UDCA | Han Ying | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
NCT05749822: Fenofibrate for Compensated Cirrhosis Patients with Primary Biliary Cholangitis |
|
|
| Recruiting | 2/3 | 104 | RoW | Fenofibrate 200mg, Placebo, UDCA | Xijing Hospital of Digestive Diseases | Primary Biliary Cholangitis | 12/25 | 12/25 | | |
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL |
|
|
| Completed | 2 | 171 | US, RoW | AZD4205 | Dizal Pharmaceuticals | Relapsed or Refractory Peripheral T Cell Lymphoma | 10/23 | 02/24 | | |
NCT06433869: The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites |
|
|
| Recruiting | 2 | 60 | RoW | serplulimab, PD-1 inhibitor, Bevacizumab, rmhTNF-NC, recombinant human tumor necrosis factor | Sun Yat-sen University | Malignant Ascites | 12/26 | 12/26 | | |
NCT05994456: Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer |
|
|
| Recruiting | 2 | 24 | RoW | PD-1 inhibitor, Toripalimab | Sun Yat-sen University | Gastric or Gastroesophageal Junction Adenocarcinoma | 12/24 | 12/24 | | |
NCT06793228: Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia |
|
|
| Not yet recruiting | 2 | 250 | RoW | Nanocrystalline Megestrol Acetate, Tislelizumab, PTOC | Henan Cancer Hospital | SCLC, Extensive Stage | 01/27 | 12/27 | | |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
CCT-ANK-11, NCT06284226: An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients |
|
|
| Withdrawn | 1 | 20 | NA | Allogeneic NK（CCT-ANK-11) | Beijing Kejing Biotechnology Co., Ltd., Beijing Kejing Biotechnology Corp. | Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer) | 06/25 | 12/25 | | |
NCT05576415: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of OC-01 in Adult Chinese With Dry Eye Disease |
|
|
| Completed | 1 | 9 | RoW | Varenicline Tartrate Nasal Spray, OC-01 (varenicline solution) Nasal Spray | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., Oyster Point Pharma, Inc. | Dry Eye Disease | 04/23 | 04/23 | | |
NCT05856513: Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment |
|
|
| Completed | 1 | 24 | RoW | ZSP1273 | Guangdong Raynovent Biotech Co., Ltd | Hepatic Impairment, Pharmacokinetics | 07/23 | 07/23 | | |
JY231、ADs, NCT06243159: JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 20 | RoW | JY231, Fludarabine, Cyclophosphamide | Shanxi Bethune Hospital | Autoimmune Diseases | 12/26 | 12/26 | | |
NCT06752746: A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera |
|
|
| Recruiting | 1 | 108 | RoW | 9MW3011 | Mabwell (Shanghai) Bioscience Co., Ltd. | Polycythemia Vera | 08/25 | 06/26 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT03893409: GIRH Chronic Obstructive Pulmonary Disease Observational Study |
|
|
| Recruiting | N/A | 10000 | RoW | | zili zhang | Chronic Obstructive Pulmonary Disease | 12/20 | 12/22 | | |
NCT05761652: An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19 |
|
|
| Recruiting | N/A | 378 | RoW | Observe and record | Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing YouAn Hospital, Kossamak Hospital, Kamuzu University of Health Sciences | COVID-19 | 02/24 | 06/24 | | |
PACER-PJI, NCT05284318: Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI. |
|
|
| Recruiting | N/A | 500 | RoW | Antibiotics treatment | First Affiliated Hospital of Fujian Medical University | Periprosthetic Joint Infection, Anti-Bacterial Agents | 12/23 | 12/26 | | |
| YUNXIN, LU |
NCT06433869: The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites |
|
|
| Recruiting | 2 | 60 | RoW | serplulimab, PD-1 inhibitor, Bevacizumab, rmhTNF-NC, recombinant human tumor necrosis factor | Sun Yat-sen University | Malignant Ascites | 12/26 | 12/26 | | |
